Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
Dapagliflozin is the first sodium-glucose co-transporter-2 inhibitor (SGLT-2i) approved for the treatment of insufficiently controlled type 2 diabetes (T2D), chronic kidney disease (CKD), and symptomatic chronic heart failure (HF)
Simple once-daily dosing. Start on 10 mg daily, stay on 10 mg daily, no need for up-titration
A starting dose of 5 mg daily is recommended for cases of severe hepatic impairment which may be increased to 10 mg if well tolerated1
Type 2 Diabetes
Dapagliflozin is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled Type 2 diabetes mellitus as an adjunct to diet and exercise:1
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
Chronic Kidney Disease
Addresses key safety considerations regarding the use of dapagliflozin in patients
CKD: Chronic Kidney Disease; eGFR: Estimated Glomerular Filtration Rate; HF: Heart Failure; MHRA: Medicines and Healthcare products Regulatory Agency; SmPC: Summary of Product Characteristics; SGLT2i: Sodium-Glucose Co-Transporter-2 Inhibitor; T2D: Type 2 Diabetes.
GB-70100 | September 2025
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
